Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Center, Open-Label, Two-Period, Two-Treatment, Randomized Sequence Study to Determine the Mass Balance and Absolute Bioavailability of a Single Oral Dose of 14C-Labeled Lofexidine Compared to a Single Intravenous Dose of Lofexidine

NCT01310296 is registered in ClinicalTrials.gov with USWM, LLC (dba US WorldMeds) as lead sponsor.

NCT NCT01310296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01310296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Center, Open-Label, Two-Period, Two-Treatment, Randomized Sequence Study to Determine the Mass Balance and Absolute Bioavailability of a Single Oral Dose of 14C-Labeled Lofexidine Compared to a Single Intravenous Dose of Lofexidine
Lead sponsor
USWM, LLC (dba US WorldMeds)
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2011
Completion date
August 31, 2011
Enrollment
12 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

normal healthy volunteers will be treated with lofexidine to understand the absolute bioavailability and mass balance recovery of the product